Clinical characteristics of patients hospitalized for COVID-19 vaccinated with at least two doses in a tertiary care hospital in Turkey

Ayşin Kılınç-Toker; Ayşe  Turunç-Özdemir; Recep Civan-Yüksel; Esma  Eryilmaz-Eren; İbrahim  Toker; İlhami  Çelik

doi:10.54034/mic.e1465

Authors

Ayşin Kılınç-Toker Attending Physician of Infectious Disease and Clinical Microbiology. Kayseri City Hospital, Department of Infectious Disease and Clinical Microbiology / Kayseri, Turkey https://orcid.org/0000-0002-6775-1234
Ayşe Turunç-Özdemir Attending Physician of Infectious Disease and Clinical Microbiology. Kayseri City Hospital, Department of Infectious Disease and Clinical Microbiology / Kayseri, Turkey
Recep Civan-Yüksel Attending Physician of Intensive Care Unit, Kayseri City Hospital, Intensive Care Units / Kayseri, Turkey https://orcid.org/0000-0003-4496-9473
Esma Eryilmaz-Eren Attending Physician of Infectious Disease and Clinical Microbiology. Kayseri City Hospital, Department of Infectious Disease and Clinical Microbiology / Kayseri, Turkey https://orcid.org/0000-0002-2712-9694
İbrahim Toker Attending Physician of Emergency Medicine. Kayseri City Hospital, Department of Emergency Medicine / Kayseri, Turkey https://orcid.org/0000-0002-5346-2116
İlhami Çelik Professor of Infectious Disease and Clinical Microbiology. Kayseri City Hospital, Department of Infectious Disease and Clinical Microbiology / Kayseri, Turkey

DOI:

https://doi.org/10.54034/mic.e1465

Keywords:

COVID-19, Vaccine, Hospitalization, Mortality

Abstract

Background. We aimed to examine the characteristics of Turkish patients hospitalized with COVID-19 despite being fully vaccinated. Method. A retrospective, single-center study was conducted in fully vaccinated patients with inactivated whole virion (CoronaVac) and/or BNT162b2 mRNA (Pfizer-BioNTech) vaccines and admitted to the hospital. We evaluated the hospitalized patients regarding the intensive care unit admission and death. A multivariate binary logistic regression analysis was used to determine the factors for mortality. Results. We conducted the study with 541 patients. The mean age was 70.2, and 52.1% of the patients were women. 73.6% of the patients were 65 years or older. The most common comorbidities were hypertension, diabetes mellitus, and COPD. The rate of the alpha variant was 54.3%, and the delta variant was 29.4%. The mortality rate was 45.8%, and the ICU admission rate was 55.3%. The delta (B.1.617.2) variant had higher ICU admission and mortality rate. Patients vaccinated with two-dose Sinovac-CoronaVac had a higher mortality rate. There was no difference between the time between the last vaccination dose to hospitalization, ICU admission, and mortality. LOS in the hospital was longer in ICU and mortality patients. In multivariate binary logistic analysis; age (odds ratio (OR), 1.06; 95% confidence intervals (95% CI) 1.04-1.08- year increase), male gender (OR, 1.57; 95% CI, 1.04-2.38), presence of comorbid diseases (OR, 4; 95% CI, 2-8) and delta variant (OR, 7.3; 95% CI, 4.4- 12.2) and vaccination with CoronaVac plus BioNTech (OR, 0.21; 95% CI, 0.07-0.62) were associated with death. Conclusion. Our results suggest administering a third and fourth dose of mRNA vaccine to subjects vaccinated primarily with two doses of CoronaVac.

References

Arregocés-Castillo L, Fernández-Niño J, Rojas-Botero M, et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet Healthy Longev. 2022 Apr;3(4):e242-e252. doi: 10.1016/S2666-7568(22)00035-6. Epub 2022 Mar 21. PMID: 35340743; PMCID: PMC8937302.

Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet. 2021 October 16;398(10309):1407–16.

Tanriover MD, Doğanay HL, Akova M, et al. efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet Lond Engl. 2021 July 17;398(10296):213–22.

Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet. 2021 May 1;397(10285):1646–57.

National Institutes of Health (NIH). Clinical Spectrum. COVID-19 Treatment Guidelines. 2021. Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/

Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. 2021;64(1):36–47.

Peric S, Stulnig TM. Diabetes and COVID-19. Wien Klin Wochenschr. 2020 Jul 1;132(13):356–61.

Gray WK, Navaratnam AV, Day J, et al. Variability in COVID-19 in-hospital mortality rates between national health service trusts and regions in England: A national observational study for the Getting It Right First Time Programme. EClinicalMedicine. 2021 May;35:100859. doi: 10.1016/ j.eclinm.2021.100859. Epub 2021 April 26. PMID: 33937732; PMCID: PMC8072185.

Mahendra M, Nuchin A, Kumar R, Shreedhar S, Mahesh PA. Predictors of mortality in patients with severe COVID-19 pneumonia - a retrospective study. Adv Respir Med. 2021;89(2):135–44.

Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022 January 1;22(1):35–42.

Bast E, Tang F, Dahn J, Palacio A. Increased risk of hospitalisation and death with the delta variant in the USA. Lancet Infect Dis. 2021 December 1;21(12):1629–30.

Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021 December 9;385(24):e84.

Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022 Apr;22(4):483–95.

Mallapaty S. China's COVID vaccines have been crucial - now immunity is waning. Nature. 2021 Oct; 598(7881): 398–9.

Grupo para estudio de vacunas SARS-CoV-2 MINSAL (vCovid MINSAL). Immunization Campaign against SARS-CoV-2 Early estimates of the effectiveness of booster shots in Chile. 2021 Oct.